À PROPOS DE CET ÉPISODE
Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:
- Introduction (0:00)
- Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)
- Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)
- Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)
- CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)
- Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)
- Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)
Anglais
États-Unis
TRANSCRIPTION 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
RECHERCHER LES ÉPISODES PASSÉS
Rechercher les épisodes précédents de Research To Practice | Oncology Videos.
AUTRES ÉPISODES DANS CE PODCAST
Featuring perspectives from Prof Susana Banerjee, including the following topics:
Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)
Mechanism of action of avutometinib/defactinib (10:16)
RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian…
Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:
Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
Current a…
Featuring a slide presentation from Dr Julia Rotow, including the following topics:
Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
Key findings from the Phase III…
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor …
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
Role…
Avertissement: Le podcast et les illustrations intégrés sur cette page proviennent de Dr Neil Love, qui est la propriété de son propriétaire et n'est ni affilié ni approuvé par Listen Notes, Inc.
MODIFIER
Merci de nous avoir aidé à tenir la base de données de podcasts à jour.
